G.A. IGNATENKO, A.E. BAGRIY, YA.S. SABELNIKOVA, I.A. ARSHAVSKAYA, I.A. GOLODNIKOV, A.YU. ANDRUSYAK

1. Gorky Donetsk National Medical University, Donetsk, Donetsk People’s Republic

Contact details:

Ignatenko G.A. — MD, Professor, Head of the Department of Propedeutics of Internal Diseases

Address: 16 Illicha Ave, 283003 Donetsk, Donetsk People’s Republic, tel.: +38 (071) 309-21-60, e-mail: gai1959@mail.ru

This literature review is devoted to the issues of non-drug and drug treatment of arterial hypertension in people with type 2 diabetes mellitus. Type 2 diabetes mellitus is the cause of severe disabling complications and a significant factor in increasing mortality. Arterial hypertension and diabetes mellitus are often combined and mutually burden each other’s course. Arterial hypertension increases the risk of formation and the rate of progression of micro- and macrovascular complications of diabetes. The presence of diabetes mellitus increases the risk of complications of hypertension by about 2 times. Achievement and stable maintenance of target blood pressure levels in people with diabetes and hypertension is one of the most important components of improving the prognosis. To do this, it is important to follow the recommendations for lifestyle changes, as well as the use of antihypertensive drugs. The article presents general issues of epidemiology and principles of determining the target level of blood pressure in different groups of patients. The issues of lifestyle changes and the choice of tactics for prescribing medications are discussed in detail, a brief description of the main groups of antihypertensive drugs is given.

Key words: arterial hypertension, type 2 diabetes mellitus, hypotensive drugs.

REFERENCES

1. Dedov I.I., Shestakova M.V., Mayorov A.Yu. et al. Type 2 diabetes mellitus in adults. Clinical recommendations. Sakharnyy diabet, 2020, vol. 23, no. S2, pp. 4–102 (in Russ.).
2. Babkin A.P. Optimization of the treatment of arterial hypertension in patients with diabetes mellitus. Sistemnyy analiz i upravlenie v biomeditsinskikh sistemakh, 2020, no. 19 (4), pp. 37−41 (in Russ.). DOI: 10.36622/VSTU.2020.19.4.005
3. Leslie W.S., Ali E., Harris L. et al. Antihypertensive medication needs and blood pressure control with weight loss in the Diabetes Remission Clinical Trial (DiRECT). Diabetologia, 2021, vol. 64, pp. 1927–1938, 31 May 2021. DOI: 10.1007/s00125-021-05471-x Epub ahead of print. PMID: 34056684.
4. Unger T., Borghi C., Charhcar F. et al. International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension, 2020, vol. 75 (6), rr. 1336−1357. DOI: 10.1161/HYPERTENSIONAHA.120.15026
5. American Diabetes Association. Microvascular Complications and Foot Care. Diabetes Care, 2021, vol. 44 (Suppl 1), rr. S151−S167. doi: 10.2337/dc21-S011
6. Cosentino F., Grant P.J., Aboyans V. et al. 2019 ESC Guidelines on Diabetes, Pre-Diabetes, and Cardiovascular Diseases Developed in Collaboration with the EASD. Eur. Heart J, 2020, vol. 41, rr. 255−323. DOI: 10.1093/eurheartj/ehz486
7. American Diabetes Association. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2021. Diabetes Care, 2021, vol. 44 (1), rr. S125–S150. DOI: 10.2337/dc21-S010
8. Ott C., Schmieder R.E. Diagnosis and treatment of arterial hypertension. Kidney Int, 2022, vol. 101 (1), pp. 36–46. DOI: 10.1016/j.kint.2021.09.026 Epub 2021 Oct 29. PMID: 34757122.
9. Viigimaa M., Sachinidis A., Toumpourleka M. et al. Macrovascular Complications of Type 2 Diabetes Mellitus. Curr. Vasc. Pharmacol, 2020, vol. 18 (2), rr. 110–116. DOI: 10.2174/1570161117666190405165151
10. Oliveros E., Patel H., Kyung S. et al. Hypertension in older adults: Assessment, management, and challenges. Clin. Cardiol, 2020, vol. 43 (2), rr. 99–107. DOI: 10.1002/clc.23303
11. Al-Makki A., DiPette D., Whelton P.K. et al. Hypertension Pharmacological Treatment in Adults: A World Health Organization Guideline Executive Summary. Hypertension, 2022, vol. 79 (1), pp. 293–301. DOI: 10.1161/HYPERTENSIONAHA.121.18192 Epub 2021 Nov 15. PMID: 34775787; PMCID: PMC8654104.
12. American Diabetes Association; Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care, 2021, vol. 44 (1), pp. S100–S110. doi: 10.2337/dc21-S008
13. American Diabetes Association; Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care, 2021, vol. 44 (1), pp. S34–S39. DOI: 10.2337/dc21-S003
14. Algoritmy spetsializirovannoy meditsinskoy pomoshchi bol’nym sakharnym diabetom, pod red. I.I. Dedova, M.V. Shestakovoy, A.Yu. Mayorova. Vyp. 10 []. Moscow, 2021. Pp. 34–35, 136–141.
15. Krivonos N.Yu., Kolomiets V.V. Diabetic nephropathy and arterial hypertension: topical issues of nephroprotection. Universitetskaya klinika, 2020, no. 4 (37), pp. 77−83 (in Russ.). DOI: 10.26435/uc.v0i4(37).596
16. Simões Corrêa Galendi J., Leite R.G.O.F., Banzato L.R., Nunes-Nogueira V.D.S. Effectiveness of Strategies for Nutritional Therapy for Patients with Type 2 Diabetes and/or Hypertension in Primary Care: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health, 2022, vol. 19 (7), pp. 42–43. DOI: 10.3390/ijerph19074243 PMID: 35409925; PMCID: PMC8998242.
17. Budhwani H., De P., Sun R. Perceived Stigma in Health Care Settings Mediates the Relationships Between Depression, Diabetes, and Hypertension. Popul Health Manag, 2022, vol. 25 (2), pp. 164–171. DOI: 10.1089/pop.2021.0268
18. Chulkov V.S., Gavrilova E.S., Chulkov V.S. et al. Primary prevention of cardiovascular diseases: emphasis on the correction of behavioral risk factors. Rossiyskiy kardiologicheskiy zhurnal, 2021, no. 26 (3S), pp. 42–78 (in Russ.). doi: 10.15829/1560-4071-2021-4278
19. Bousquet P., Hudson A., García-Sevilla J.A., Li J.-X. Imidazoline Receptor System: The Past, the Present, and the Future. Pharmacol. Rev, 2020, vol. 72 (1), rr. 50–79. DOI: 10.1124/pr.118.016311
20. Chazova I.E., Shestakova M.V., Zhernakova Yu.V et al. Russian Medical Society for Arterial Hypertension. Recommendations for the management of patients with arterial hypertension with metabolic disorders and type 2 diabetes mellitus. Sistemnye gipertenzii, 2020, vol. 17, no. 1, pp. 7–45 (in Russ.). DOI: 10.26442/2075082X.2020.1.200051
21. Boeva V.V., Zav’yalov A.N. Drug prevention of type 2 diabetes mellitus in patients with early disorders of carbohydrate metabolism: effectiveness and clinical outcomes in long-term follow-up. Vestnik RGMU, 2020, no. 2, pp. 81–88 (in Russ.). DOI: 10.24075/vrgmu.2020.014
22. Asfandiyarova N.S. Mortality in type 2 diabetes. Sakharnyy diabet, 2015, vol. 18, no. 4, pp. 12–21 (in Russ.). DOI: HYPERLINK «https://doi.org/10.14341/DM6846» HYPERLINK «https://doi.org/10.14341/DM6846″HYPERLINK «https://doi.org/10.14341/DM6846″10.14341HYPERLINK «https://doi.org/10.14341/DM6846″/DMHYPERLINK «https://doi.org/10.14341/DM6846″6846
23. Ignatenko G.A., Mukhin I.V., Gavrilyak V.G. et al. Syndrome of metabolic disorders and its correction in patients with comorbid cardiac pathology, etc. Universitetskaya klinika, 2018, no. 1 (26), pp. 46–53 (in Russ.). DOI: 10.26435/uc.v0i1(26).121
24. Ignatenko G.A., Bagriy A.E., Oprishchenko A.A. et al. Sakharnyy diabet: rukovodstvo dlya vrachey [Diabetes mellitus: a guide for doctors]. Donetsk: RB Pozitiv, 2022. 640 p.